HEPA News and Press, Hepion Pharmaceuticals Inc. From 02/19/24

International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...

2024-02-16 08:35:34 ET More on ContraVir Hepion Pharma announces restructuring plan, sees $400–800 thousand charge for 4Q Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir ...

2024-02-16 08:27:44 ET Losers: Trupanion TRUP -24% after Q4 earnings release . Bloom Energy Corp BE -19% after Q4 earnings release . Infobird Co Ltd ( IFBD ) -20% . Greenpro Capital Corp ( GRNQ ) -16% . Roku ROKU -17% after Q4 earn...

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic dis...

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

2023-12-07 08:35:58 ET More on Hepion Hepion to sell $5M in shares through registered direct offering Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir For further details see: ...

Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, ...

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASHȁ...

2023-11-28 11:37:19 ET More on Hepion Hepion to sell $5M in shares through registered direct offering Hepion Pharmaceuticals' CMO Todd Hobbs resigns Seeking Alpha’s Quant Rating on ContraVir For further details see: Hepion Pharmaceuticals says Wijn...

AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...